Almirall SA : Q2 2024 EBITDA in line, FY 2024 guidance reiterated
>Modest EBITDA growth despite the material SG&A and R&D efforts - Sales reached € 251m (+7% y-o-y vs +7% in Q1 2024 and -5% in Q4 2023), broadly in line with our estimates and the consensus. As regards its recent product launches: Ilumetri posted strong double-digit growth, albeit decelerating q-o-q, despite facing a hard comp (+22% in Q2 vs +29% in Q1 2024 and +39% in Q2 2023), Ebglyss’ contribution to sales was € 7m equating to a +100% q-o-q growth and Seysara impro...Almirall is engaged in the acquisition, manufacture, storage, sale and mediation in the sale of pharmaceutical specialties and products and all manner of raw materials used to prepare pharmaceutical specialties and products. Also, Co. acquires, manufactures, storages, sales and mediates in the sale of cosmetics, chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food-industry use, as well as all manner of utensils, complements and accessories for the chemical, pharmaceutical and clinical industries. In addition, Co. is engaged in the acquisition, sale, lease, subdivision and development of land lots, land and properties of all kinds.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.